(Q40522817)

21 September 2017

title

Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer (English)

1 reference

21 September 2017

1 reference

7

Jodi A Flaws

1 reference

21 September 2017

Lisa Gallicchio

1

1 reference

21 September 2017

Gwyn Lord

2

1 reference

21 September 2017

Katherine Tkaczuk

3

1 reference

21 September 2017

Malcolm Danton

4

1 reference

21 September 2017

Lynn M Lewis

5

1 reference

21 September 2017

Chang K Lim

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Breast Cancer Research and Treatment

21 September 2017

published in

1 reference

21 September 2017

volume

85

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

89-97

1 reference

Tamoxifen metabolism: pharmacokinetic and in vitro study

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

The pharmacology and clinical uses of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

On-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoxifen metabolism

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tamoxifen metabolism in rat liver microsomes: identification of a dimeric metabolite derived from free radical intermediates by liquid chromatography/mass spectrometry.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Clinical uses of antiestrogens

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Long-term tamoxifen citrate use and potential ocular toxicity

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Eye problems in breast cancer patients treated with tamoxifen.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Intraocular penetration of tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Ocular complications of systemic cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tamoxifen blocks chloride channels. A possible mechanism for cataract formation.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000021050.92539.B0

7 January 2021

10.1023/B:BREA.0000021050.92539.B0

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

1028829002

0 references

1 reference